Tardive Dyskinesia Following Low-Dose Risperidone

Tardive dyskinesia is an involuntary athetoid or choreiform movement lasting a minimum of a few weeks. It is associated with the use of neuroleptic medication for at least three months and persists beyond four to eight weeks. Tardive dyskinesia usually occurs as a result of the long-term use of dopa...

Full description

Saved in:
Bibliographic Details
Published inCurēus (Palo Alto, CA) Vol. 14; no. 12; p. e32319
Main Authors Rokon, Ahmad E, Alsomali, Faisal A, Alrasheed, Malek A, Alharbi, Abdulrahman D, Alhamadh, Moustafa S, Alqahtani, Abdulmajeed M, Alhamidy, Farah K, Alotaibi, Meshal R
Format Journal Article
LanguageEnglish
Published United States Cureus Inc 08.12.2022
Cureus
Subjects
Antipsychotics
Case reports
Dopamine
Dyskinesia
Emergency medical care
Mental disorders
Mental health
Neurology
Psychiatry
Psychosis
Psychotropic drugs
Young adults
Saudi Arabia
Riyadh Saudi Arabia
movement disorder
extrapyramidal symptoms
neurology
psychosis
tardive dyskinesia
Online AccessGet full text

Cover

More Information
Summary:Tardive dyskinesia is an involuntary athetoid or choreiform movement lasting a minimum of a few weeks. It is associated with the use of neuroleptic medication for at least three months and persists beyond four to eight weeks. Tardive dyskinesia usually occurs as a result of the long-term use of dopamine receptor-blocking agents, mainly first-generation antipsychotics or a high-dose, second-generation antipsychotic. We present a case of a 28-year-old female with osteogenesis imperfecta presented later with major depressive disorder with psychotic features. She was given a low-dose second-generation antipsychotic, namely, risperidone (2 mg) for psychosis for a cumulative duration of three months. As a result, she developed extrapyramidal symptoms in the form of akathisia, axial dystonia, involuntary movement of the right hand, and smacking movement of the lips. Symptoms persisted for more than eight weeks despite discontinuing risperidone and switching to quetiapine. After the exclusion of other differential diagnoses, she was labeled as a case of tardive dyskinesia. More studies are needed to assess whether undiscovered contributing factors to tardive dyskinesia exist and to understand how second-generation antipsychotics (SGAs) contribute to the development of tardive dyskinesia.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.32319